Federal Reserve Chair Jerome Powell has made it very clear that unlike some investors, he's not stressed out about a potential rise in inflation later this year. And there's good reason for that: he's busy worrying about jobs.
Harvard Researchers Discover Some Cancers May Originate Decades Earlier Than Previously Believed | News thecrimson.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thecrimson.com Daily Mail and Mail on Sunday newspapers.
Mar 8, 2021 8:55am Researchers from Harvard University and Massachusetts General Hospital suggested JAK inhibitors may be useful in treating Alzheimer s after using machine learning to model the response of brain neural cells to a variety of drugs. (sdecoret/iStock/Getty Images Plus)
Could janus kinase (JAK) inhibitors like Eli Lilly’s rheumatoid arthritis drug Olumiant be repurposed to treat Alzheimer’s disease? Researchers at Harvard University and Massachusetts General Hospital have set out to find the answer to that question with a new clinical trial that was born from artificial intelligence.
The researchers used a type of AI called machine learning to identify existing drugs that might be able to prevent neuronal death in Alzheimer’s. The screen pulled up a list of 15 FDA-approved drugs as candidates for repurposing in Alzheimer’s, and five of them were JAK inhibitors, they reported in the journal Nature Communications.
Very few mutations will materially alter the course of the pandemic.
“Among the numerous SARS-CoV-2 variants that have been detected, only a very small proportion are of public health concern,” US government advisor Anthony Fauci wrote in an open letter published last week in the JAMA science journal.
The English, South African and Brazilian variants, however, all share a particular mutation named N501Y that is consequential.
The mutation occurs on the virus’ spike protein, which almost certainly makes it more effective at binding with human receptor cells. As a result, these strains are more infectious.
In addition, preliminary research has shown that the South African variant renders the AstraZeneca/Oxford vaccine significantly less effective.